Yd Biopharma Limited WT (YDESW)

$0.47 -0.08 (-15.29%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 118,800
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

Address:
No. 3, Xingnan St., 12F. Nangang Dist., Taipei, Taiwan
Latest News on YDESW
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

Mar 31, 2026, 8:00 AM EDT - 4 weeks ago

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

Mar 17, 2026, 8:00 AM EDT - 6 weeks ago

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

Feb 25, 2026, 8:00 AM EST - 2 months ago

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

Jan 29, 2026, 8:30 AM EST - 3 months ago

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

Jan 6, 2026, 9:00 AM EST - 4 months ago

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

Jan 5, 2026, 9:00 AM EST - 4 months ago

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

Dec 16, 2025, 9:00 AM EST - 4 months ago

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

Dec 9, 2025, 9:00 AM EST - 5 months ago

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

Dec 2, 2025, 9:00 AM EST - 5 months ago

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

Nov 24, 2025, 9:00 AM EST - 5 months ago

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

Nov 5, 2025, 8:30 AM EST - 6 months ago

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

Oct 20, 2025, 10:20 AM EDT - 6 months ago

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

Oct 10, 2025, 8:37 AM EDT - 7 months ago

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

Sep 30, 2025, 5:25 PM EDT - 7 months ago

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

Aug 29, 2025, 7:30 AM EDT - 8 months ago

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market